Screener
Corvus Pharmaceuticals CRVS Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| General and administrative | 3,702 | 2,469 |
| Total operating expenses | 14,877 | 9,922 |
| Loss from operations | (14,877) | (9,922) |
| Interest income and other expense, net | 1,784 | 525 |
| Change in fair value of warrant liability | — | 25,129 |
| Loss before equity method investment | (13,093) | 15,732 |
| Loss from equity method investment | (599) | (539) |
| Net (loss) income | $(13,692) | $15,193 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's interest income?
- Corvus Pharmaceuticals (CRVS) reported interest income of $1.78M in Q1 2026.
- How has Corvus Pharmaceuticals's interest income changed year-over-year?
- Corvus Pharmaceuticals's interest income increased by 239.8% year-over-year, from $525K to $1.78M.
- What is the long-term trend for Corvus Pharmaceuticals's interest income?
- Over 3 years (2022 to 2025), Corvus Pharmaceuticals's interest income has grown at a 56.5% compound annual growth rate (CAGR), from $654K to $2.51M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Corvus Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude